A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

What this study is about

The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin. The study is seeking participants who: 1. Are 18 to 64 years of age; 2. Were confirmed to have AD at least 6 months ago; 3. Do not have a suitable prescribed medicine for AD; 4. Are considered by their doctors to have moderate to severe AD. The study has two stages (Stage 1 and Stage 2). In both stages, eligible participants will take either PF-08049820 or placebo as tablets by mouth daily for 12 weeks. A placebo does not have any medicine in it but looks just like the medicine being studied. Participants will visit the clinic on Day 1, Weeks 1, 2, 4, 6, 8 and 12. They will have a follow-up visit at Week 16. During this time, the participant's health and skin condition will be checked. They will have blood and urine tests. They will also have to answer questions about their health, skin condition, and how much their skin condition affects their lives. The experiences of participants receiving the study medicine will be compared to those receiving placebo. This will help to understand if PF-08049820 is safe and effective.

Who can join (things the study team will check)

✅ You may be able to join if…

• Are 18 to 64 years of age
• Have clinical diagnosis of AD for at least 6 months prior to Day 1 and have diagnosis of AD confirmed by photographs
• Have moderate to severe AD as defined by the following at screening and baseline visits: AND -Peak Pruritis Numeric Rating Scale (PP-NRS) greater than or equal to 4 at screening and a weekly average of greater than or equal to 4 at baseline visit
  • Affected body surface area (BSA) greater than or equal to 10% and up to 60%;
  • Validated Investigator's Global Assessment (vIGA) greater than or equal to 3;
  • Eczema Area and Severity Index (EASI) greater than or equal to 16;
• Do not have a suitable prescribed medicine for AD.
• Body Mass Index (BMI) of 18 to 38 kg/m2 and a total body weight greater than 48 kg (106 lbs)

🚫 You may not be able to join if…

• Have an infection that requires treatment
• Have other skin conditions other than AD
• Have severe uncontrolled asthma
• Regular use (more than 2 visits per week) of a tanning booth or phototherapy for AD within 4 weeks of the screening visit

Where this trial is running

• Marvel Clinical Research, Huntington Beach, California, United States
• Metropolis Dermatology - DTLA, Los Angeles, California, United States
• Northridge Clinical Trials, Northridge, California, United States
• Clinical Science Institute, Santa Monica, California, United States
• Gsi Clinical Research, Margate, Florida, United States
• Skin Research of South Florida, Miami, Florida, United States
• Montefiore - Jacobi Dermatology Clinic, The Bronx, New York, United States
• Montefiore - Clinical Research Center, The Bronx, New York, United States
• Montefiore - Greene Medical Arts Pavillion, The Bronx, New York, United States
• Montefiore - The Dermatology Center, The Bronx, New York, United States
• Montefiore Medical Center, The Bronx, New York, United States
• UPMC Department of Dermatology, Pittsburgh, Pennsylvania, United States

+ 8 more sites.

Who to contact

Pfizer CT.gov Call Center · 1-800-718-1021 · ClinicalTrials.gov_Inquiries@pfizer.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07216027.